Microsoft's AI for Health supports COVID-19 vaccine development

IMAGE: Covax-19 is an Australian-developed COVID-19 vaccine developed with the help of computational and artificial intelligence (AI)-based technologies. Given the global urgency of the COVID-19 pandemic, Microsoft's AI for Health program has stepped in to support the development and potential deployment of Vaxine's COVAX-19 vaccine with a philanthropic grant. Vaxine Pty Ltd, a biotechnology company based in South Australia, uses computational and artificial intelligence (AI)-based technologies to accelerate pandemic vaccine and drug development with the aim to reduce drug development processes that normally take decades down to just weeks. The Microsoft AI and Azure cloud capabilities will help the company accelerate clinical testing of its COVAX-19 vaccine. "Large international Phase 3 vaccine trials are extraordinarily complex and generate vast amounts of data that needs to be efficiently processed", says Vaxine Research Director, Flinders University Professor Nikolai Petrovsky.